Form 4: ImmunityBio Director Wesley Clark Acquires Stock Options
SEC Form 4 Filing
Wesley Clark, a director at ImmunityBio, acquired stock options for 77,633 shares of common stock on June 11, 2024.
Summary
- On June 11, 2024, Wesley Clark, a director of ImmunityBio, Inc. (IBRX), acquired stock options to purchase 77,633 shares of the company's common stock.
- The exercise price of these options is $5.96 per share.
- The options vest on the earlier of June 11, 2025, or the day before the next annual meeting of stockholders, contingent upon Clark's continued service to the company.
- The options expire on June 11, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a stock option grant to a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.
Stakeholder Impact
- The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 06/11/2024 | Date of the stock option transaction. |
| 06/11/2025 | Earliest vesting date for the stock options, contingent upon continued service. |
| 06/13/2024 | Date of signature for the Form 4 filing. |
| 06/11/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.